A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors

By afschroeder • March 1, 2026

Falchook G, Braganca Xavier C, Van Veenhuyzen D, Malhotra J, Sadeghi S, Kalebasty AR, Wood L, Rahman F, Li E, Pak Y, Khalil M, Spira AI, Sommerhalder D, Garrido-Laguna I, Hong DS. A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors. NPJ Precis Oncol. 2026 Feb 28. doi: 10.1038/s41698-026-01340-1. Epub ahead of print. PMID: 41764244.

Tags: Hematology/Oncology, Publications

Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia

Zuckerman JE, Larson S, Abdelnour L. Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia. Kidney Med. 2026 May 12;8(7):101402. doi:[...]

Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer

Mouabbi JA, Lipsyc-Sharf MD, Yan F. Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):1-16.[...]

Interpreting MRD results and integrating assays into practice

Lipsyc-Sharf MD. Interpreting MRD results and integrating assays into practice. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):7-11. PMID: 42283708.